Biocytogen and Nanjing Chia Tai Tianqing Announce IND Approval in China for Co-Developed Anti-IGF-1R Antibody NTB003 (BCG009)
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) and Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. (“NJCTTQ”) announced that NTB003 (formerly BCG009), a co-developed injectable drug candidate, has received the Investigational New Drug (IND) approval from the National Medical Products Administration (NMPA). The approved indication is Thyroid Eye Disease (TED).
About NTB003 Injection
NTB003 is a second-generation fully human anti-IGF-1R monoclonal antibody co-developed by Biocytogen and Nanjing Chia Tai Tianqing. Antibody discovery and optimization were completed by Biocytogen using its proprietary RenMab™ fully human antibody discovery platform, while Nanjing Chia Tai Tianqing was responsible for CMC process development, GLP-compliant toxicology studies, and IND application. Compared with first-generation approved anti-IGF-1R therapeutics, NTB003 demonstrates enhanced molecular affinity, improved druggability, and an extended half-life. In vitro studies have shown that NTB003 exerts potent signal-blocking activity and effectively inhibits the release of hyaluronic acid (HA), indicating strong potential for further clinical development.
Clinical studies of teprotumumab and other investigational anti-IGF-1R biologics have demonstrated that targeting IGF-1R can deliver significant clinical benefits. These agents have shown rapid onset of therapeutic response and favorable outcomes in reducing proptosis and diplopia, improving quality of life, and lowering clinical activity scores in patients with TED.
Nanjing Chia Tai Tianqing will lead the clinical development and commercialization of NTB003 in China, aiming to provide an improved therapeutic option for Chinese TED patients. Biocytogen will be responsible for the global out-licensing of the product outside China.
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® (RenMab™/ RenLite®/ RenNano®/ RenTCR-mimic™ ) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2024, approximately 200 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit http://en.biocytogen.com.cn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250604359716/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ABB's Dr. Matthew Wise and Andressa Ferraz Named Among Future of Field Service's 2025 Stand Out 50 Leaders1.10.2025 03:00:00 CEST | Press release
ABB Electrification Service leaders recognized for driving innovation in energy storage solutions and customer-centric service strategies. Highlights leadership in enabling next-generation service models in line with evolving customer needs for energy resilience and digitalization Underscores ABB Electrification Service’s commitment to helping industries modernize critical infrastructure, extend asset lifetimes, and accelerate the shift to smarter, cleaner, and more circular operations Two leaders from ABB Electrification Service have been named among the Future of Field Service's prestigious 2025 Stand Out 50 Leaders. Dr. Matthew Wise, Global Head of Strategy & Business Development, and Andressa Ferraz, Sustainability Advisory Service Manager for EMEA were selected for their outstanding contributions in redefining field service innovation and their roles in developing customer-centric energy solutions. This press release features multimedia. View the full release here: https://www.bus
EIG’s MidOcean Energy to Acquire Interest in LNG Canada from PETRONAS30.9.2025 17:57:00 CEST | Press release
MidOcean Energy (“MidOcean”), a liquefied natural gas (LNG) company formed and managed by EIG, a leading institutional investor in the global energy and infrastructure sectors, today announced it has entered into definitive agreements to acquire a 20% interest in PETRONAS’ key entities in Canada. The transaction includes a 20% interest in the North Montney Upstream Joint Venture (“NMJV”), which hold PETRONAS’ upstream investment in Canada, and a 20% interest in the North Montney LNG Limited Partnership (“NMLLP”), which holds PETRONAS’ 25% participating interest in the LNG Canada Project. LNG Canada is Canada’s first LNG export project and represents a strategically significant development supplying LNG into Asia at a competitive cost of supply. LNG Canada shipped its first LNG cargo earlier this year. The NMJV is a partnership that holds more than 800,000 gross acres of mineral rights with 53 trillion cubic feet of reserves and contingent resources. Following completion of the transact
AT&T Selects STREAMWIDE to Power the FirstNet Next-Generation Mission-Critical Application for Public Safety in the U.S.30.9.2025 17:45:00 CEST | Press release
AT&T has selected STREAMWIDE to power its next-generation mission-critical solution for FirstNet®, Built with AT&T, the only network built with and for America’s first responders. Currently FirstNet supports more than 30K public safety agencies and organizations. Based on the 3GPP standard for mission-critical services (MCX), which includes push-to-talk, video, data, and command & dispatch, the solution introduces next-generation capabilities that go far beyond traditional radio networks currently used by first responders, including police, fire, EMS, and other critical services. Through this collaboration, AT&T integrates STREAMWIDE’s field-proven mission-critical technology into its portfolio, creating a cutting-edge solution designed for the most demanding environments. Key benefits for public safety and mission-critical organizations include: 3GPP-compliant MCX services offering push-to-talk, secure multimedia, geolocation, real-time video, secure messaging, and more – across a lar
Metr: Crowdfunding to Combat Rising Energy Costs30.9.2025 16:07:00 CEST | Press release
metr technologies enable energy savings of up to 35% – without construction work or loss of comfort. metr partners with Europe’s leading impact investment platform to cut CO₂ emissions. Landlords and tenants are facing tough times at the start of the new heating season: heating and CO2 costs are forecast to rise significantly. At the same time, the EU has revised its Buildings Directive. The building sector must reduce its CO2 emissions to meet climate targets. Berlin-based PropTech company metr offers a solution for greater energy efficiency without extensive building restoration: digital heating optimization enables energy savings of up to 35 percent in existing building stock. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250930569771/en/ Private individuals can support the development of energy efficiency solutions for existing buildings while benefiting as investors from the company’s increasing value. metr develops te
Cicero & Bernay Marks 20 Years with an Identity Built for Tomorrow30.9.2025 15:54:00 CEST | Press release
C&B steps into its next chapter, Empowered by Facts, combining innovation, intelligence, and a human touch to guide what comes next Cicero & Bernay (C&B), a communication advisory redefining how brands connect strategy, design, and digital intelligence, celebrates 20 years with a renewed role built for today’s fast-changing business environment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250930935923/en/ Ahmad Itani, CEO and Founder of C&B (Photo: AETOSWire) This evolution goes beyond a new look. It establishes C&B as a partner where facts create foresight, and creativity turns it into influence. With every discipline connected under one approach, the consultancy moves forward as: Empowered by Facts. Ahmad Itani, CEO and Founder of C&B, said, “Our new identity is a declaration of who we are today. For years, we let the facts speak. Now, they give us the perspective to look ahead and act as true strategic advisors. We gui
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom